Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 16Unknown 2Terminated 2Active not recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 5Other hematologic neoplasm 3Lymphoid 3Genitourinary 2Breast 2Tumor-Agnostic 1Other neoplasm 1Myeloid 1Gynecologic 1Gastrointestinal 1CNS 1

Conditions

Carcinoma, Renal Cell 2

Interventions

Docetaxel 69pembrolizumab 48Prednisone 43Nivolumab 40enzalutamide 38Gemcitabine 37Sunitinib 36Cyclophosphamide 29Radiotherapy 26Magnetic Resonance Spectroscopy 26Leuprolide 25Abiraterone Acetate 25Sorafenib 23Everolimus 23Cisplatin 23bicalutamide 19atezolizumab 18Carboplatin 18Bevacizumab 18avelumab 17Radiosurgery 17Goserelin 17Interleukin-2 16abiraterone 15fludarabine 14Doxorubicin 14olaparib 13durvalumab 13cabozantinib 13acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Interferon alpha-2 × Genitourinary × Clear all
NCT00098618 2013-07-02

Sorafenib and Interferon Alfa in Treating Patients With Locally Advanced or Metastatic Kidney Cancer

National Cancer Institute (NCI)

Phase 2 Terminated
40 enrolled
Genitourinary

Carcinoma, Renal Cell

NCT00561912 2011-12-26

Low Dose Decitabine + Interferon Alfa-2b in Advanced Renal Cell Carcinoma

M.D. Anderson Cancer Center

Phase 2 Terminated
2 enrolled 3 charts
Genitourinary

Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡